Skip to main content
. 2014 Aug 8;9(8):e104561. doi: 10.1371/journal.pone.0104561

Table 1. Overview of MRSA clone characteristics, site of isolation, and biofilm formation in static and shear flow assays.

MRSA clone (No. of strains) Clonal complex SCCmec type Sequence type Presence of pvl/ACME Site of isolation Biofilm formation in static assay** Biofilm formation in shear flow assay
Strong formers (n) Moderate formers (n) Weak formers (n) + (n) − (n)
Southern Germany (6) 5 I 228/5 Nares (n = 4) Respiratory tract (n = 1) Nk *(n = 1) 1 2 3 3 3
New York/Japan (4) 5 II 5/496 Abscess/wound (n = 2) Blood (n = 1) Nk (n = 1) 0 4 0 3 1
Iberian (4) 8 I 247/336 Abscess/wound (n = 1) Respiratory tract (n = 1) Stool (n = 1) Nk (n = 1) 1 2 1 2 2
Hungarian/Brazilian (12) 8 III 239/241 Abscess/wound (n = 5) Respiratory tract (n = 4) Nares (n = 1) Blood (n = 2) 5 3 4 8 4
EMRSA-16 (4) 30 II 36 Nares (n = 2) Abscess/wound (n = 1) Nk (n = 1) 1 2 1 3 1
USA600 (3) 45 II 45 Nares (n = 1) Nk (n = 2) 0 0 3 3 0
Pediatric (5) 5 IV 5 Abscess/wound (n = 3) Respiratory tract (n = 1) Nares (n = 1) 3 1 1 0 5
USA500 (8) 8 IV 8 Abscess/wound (n = 2) Nares (n = 2) Urinary tract (n = 1) Nk (n = 3) 8 0 0 3 5
USA300 (3) 8 IV 8 pvl/ACME Abscess/wound (n = 2) Blood (n = 1) 3 0 0 3 0
EMRSA-15 (7) 22 IV 22 Nares (n = 2) Respiratory tract (n = 1) Blood (n = 1) Nk (n = 3) 7 0 0 5 2
South-West Pacific (2) 30 IV 30 Abscess/wound (n = 1) Respiratory tract (n = 1) 0 1 1 0 2
South-West Pacific (3) 30 IV 30 pvl Abscess/wound (n = 3) 0 1 2 0 3
Berlin (11) 45 IV 45 Abscess/wound (n = 4) Respiratory tract (n = 4) Urinary tract (n = 2) Nares (n = 1) 3 6 2 5 6
European (4) 80 IV 80 pvl Abscess/wound (n = 3) Nares (n = 1) 3 1 0 1 3

*Nk, Not known; **Defined cut-offs for strong, moderate, and weak biofilm formers (OD492: >0.027, 0.027–0.009, and <0.009, respectively).

HHS Vulnerability Disclosure